



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/765,456	01/26/2004		John C. Kennell	SLU02-010	8365	
33436	7590	04/07/2006		EXAMINER		
SAINT LO	UIS UNI	VERSITY	GUZO, DAVID			
OFFICE OF 3556 CARO		CH ADMINISTRAT	ART UNIT	PAPER NUMBER		
ST. LOUIS,			1636			
				DATE MAILED: 04/07/200	6	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
	10/765,456	KENNELL, JOHN C.	
Office Action Summary	Examiner	Art Unit	
	David Guzo	1636	
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address	
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).	
Status			
 1) Responsive to communication(s) filed on 26 Ag 2a) This action is FINAL. 2b) This 3) Since this application is in condition for allowant closed in accordance with the practice under E 	action is non-final.		
Disposition of Claims			
4)	vn from consideration.		
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the of Replacement drawing sheet(s) including the correction in the oath or declaration is objected to by the Examiner	epted or b) objected to by the lidrawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).	
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list of	s have been received. s have been received in Applicati ity documents have been receive (PCT Rule 17.2(a)).	on No ed in this National Stage	
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary Paper No(s)/Mail Da	ate	
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	6) Other:	atent Application (PTO-152)	

Application/Control Number: 10/765,456 Page 2

Art Unit: 1636

Election/Restriction

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-4, 6, 8-16, drawn to an isolated polynucleotide that comprises a sequence that encodes a reverse transcriptase (RT) polypeptide or fragment thereof wherein the RT is encoded by SEQ ID NO:3 or a sequence which encodes a RT polypeptide that comprises a sequence having 88% identity to SEQ ID NO:1 (encoded by SEQ ID NO:3), a vector comprising said sequence, cells containing said polynucleotide and a method of making a pFOXC-RT polypeptide, classified in class 536, subclass 23.1.
- II. Claims 1-3, 5, 7-16, drawn to an isolated polynucleotide that comprises a sequence that encodes a reverse transcriptase (RT) polypeptide or fragment thereof wherein the RT is encoded by SEQ ID NO:4 or a sequence which encodes a RT polypeptide that comprises a sequence having 88% identity to SEQ ID NO:2 (encoded by SEQ ID NO:4), a vector comprising said sequence, cells containing said polynucleotide and a method of making a pFOXC-RT polypeptide, classified in class 435, subclass 325.
- III. Claims 8-10, 15-16, drawn to an isolated polynucleotide SEQ ID NO:5, vectors containing said polynucleotide and a method of making a pFOXC-RT polypeptide, classified in class 435, subclass 69.1.

IV. Claims 8-10, 15-16, drawn to an isolated polynucleotide SEQ ID NO:6, vectors containing said polynucleotide and a method of making a pFOXC-RT polypeptide, classified in class 435, subclass 320.1.

- V. Claims 17-22, drawn to a method of making a complementary DNA molecule comprising combining a template polynucleotide molecule with a pFOXC-RT polypeptide having a sequence at least 88% identical to SEQ ID NO:1, classified in class 435, subclass 91.1.
- VI. Claims 17-22, drawn to a method of making a complementary DNA molecule comprising combining a template polynucleotide molecule with a pFOXC-RT polypeptide having a sequence at least 88% identical to SEQ ID NO:2, classified in class 435, subclass 91.5.

The inventions are distinct, each from the other because of the following reasons:

Inventions I, II, III and IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different designs, modes of operation, and effects (MPEP § 802.01 and § 806.06). In the instant case, the different inventions each involve a distinct polynucleotide sequence (SEQ ID NO:3-6 and a method of using said sequence. Each polynucleotide sequence has a distinct nucleotide sequence and a search of one would not be co-extensive with a search of the others and hence would be burdensome. Each invention is capable of supporting a separate patent.

Inventions I-IV and V-VI are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different

Application/Control Number: 10/765,456

Art Unit: 1636

designs, modes of operation, and effects (MPEP § 802.01 and § 806.06). In the instant case, the different inventions involve nucleic acid sequences and methods of use of said sequences to make polypeptides (Groups I-IV) while the methods of Groups V-VI involve use of RT polypeptides to make a complementary DNA copy of a template DNA. The methods of Groups V-VI can be practiced without the DNAs of Groups I-IV. Additionally, the method of Groups I-IV involves use of a DNA encoding a pFOXC-RT polypeptide to express said polypeptide while the methods of Groups V-VI involves the unrelated process of making a complementary DNA using a pFOXC-RT polypeptide in an in vitro technique. A search of one method would not be co-extensive with a search of the others and hence would be burdensome.

Because these inventions are independent or distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Art Unit: 1636

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Guzo, PhD, whose telephone number is (571) 272-0767. The examiner can normally be reached on Monday-Thursday from 8:00 AM to 5:30 PM. The examiner can also be reached on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Irem Yucel, PhD, can be reached on (571) 272-0781. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

David Guzo April 1, 2006

PRIMARY EXAMPLER